Daily Sepsis Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
Mechanistic and translational sepsis research advanced on three fronts: PP4 was identified as a key brake on CCL5/CCR5-driven NETosis, a 12-gene signature robustly distinguished sepsis from SIRS with causal support for EIF4G3, and aging-associated gut microbiota were implicated in intestinal barrier breakdown and heightened sepsis susceptibility. Together, these studies propose actionable pathways, diagnostic tools, and microbiome targets.
Research Themes
- Innate immune regulation and NETosis control via the PP4–CCL5/CCR5 axis
- Genomic diagnostics and causal inference to distinguish sepsis from SIRS
- Aging gut microbiota driving intestinal barrier dysfunction and sepsis susceptibility
Selected Articles
1. PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis.
Using myeloid-specific knockout mice, the authors show that PP4 restrains macrophage-derived CCL5/CCR5 signaling, limiting PAD4-dependent NETosis, ROS, and elastase activity in sepsis models. PP4 dephosphorylates TBK1 to inactivate IRF3 and reduce CCL5, while ERK1/2-driven CCR5 upregulation in PP4-deficient neutrophils amplifies NETosis; CCR5 inhibition and PP4 reconstitution attenuate hyperactivation.
Impact: Identifies PP4 as a tractable node controlling CCL5/CCR5-driven NETosis and innate immune crosstalk, revealing a new therapeutic axis in sepsis. The multi-tiered mechanistic dissection strengthens causal inference.
Clinical Implications: While preclinical, findings nominate the CCL5/CCR5 pathway and PP4 activity as targets to temper neutrophil hyperactivation and NETosis in sepsis. CCR5 inhibitors or strategies enhancing PP4 function could be explored to reduce organ injury.
Key Findings
- Myeloid-specific PP4 deficiency increases mortality and tissue injury after CLP or endotoxin challenge.
- Loss of PP4 augments macrophage-derived CCL5, driving CCR5-mediated PAD4-dependent NETosis, ROS, and elastase activity; CCR5 inhibition mitigates this.
- PP4 directly dephosphorylates TBK1 to inactivate IRF3 and suppress CCL5; ERK1/2 phosphorylation upregulates CCR5 in PP4-deficient neutrophils; WT PP4 transfection reduces LPS-induced CCR5 and NETs.
Methodological Strengths
- Use of myeloid cell-specific PP4 knockout mice with both CLP and endotoxin sepsis models
- Mechanistic validation with CCR5 pharmacologic inhibition and PP4 wild-type versus phosphatase-deficient mutant rescue
Limitations
- Preclinical mouse and in vitro data without interventional human studies
- Scope of human validation limited to expression patterns; safety and efficacy of targeting PP4/CCR5 in sepsis remain untested clinically
Future Directions: Test CCR5 blockade and PP4-modulating strategies in translational sepsis models and early-phase clinical studies; delineate cell-type specific PP4 regulation and off-target risks.
Sepsis is a life-threatening clinical syndrome caused by a dysregulated innate immune response to infection, resulting in excessive systemic inflammation, multi-organ failure, and persistently high mortality rates. In fatal human sepsis, PP4 expression is markedly reduced in myeloid cells, suggesting a protective role against dysregulated innate immunity. However, its role in macrophage-neutrophil crosstalk during sepsis environment remains unclear. To delineate its cell-type specificity, we generated myeloid cell-specific PP4 knockout mice and investigated PP4's function in innate immune regulation during sepsis. PP4-deficient mice exhibited significantly increased susceptibility to sepsis, with severe tissue damage following cecal ligation and puncture (CLP) or endotoxin challenge. Mechanistically, PP4 modulates macrophage-neutrophil crosstalk during the sepsis environment, with its loss leading to dysregulated CCL5/CCR5 signaling, driving excessive neutrophil activation. Elevated macrophage-derived CCL5 enhanced PAD4-dependent NETosis, ROS production, and elastase activity via CCR5, while CCR5 inhibition effectively mitigated neutrophil hyperactivity. At the molecular level, PP4 directly dephosphorylated TBK1, thereby inactivating IRF3 and suppressing macrophage-driven CCL5 production. Furthermore, ERK1/2 phosphorylation upregulated CCR5 expression in PP4-deficient neutrophils post-CLP, amplifying the CCL5/CCR5-mediated NETosis response. Notably, transfection with wild-type PP4-but not a phosphatase-deficient mutant-reduced LPS-mediated CCR5 expression in neutrophils, thereby limiting ROS production and NETs formation. These findings establish PP4 as a critical regulator of CCL5/CCR5-driven NETosis, uncovering a novel therapeutic target for modulating innate immune responses in sepsis.
2. From machine learning to causal insight: a robust 12-gene signature to distinguish sepsis risk from systemic inflammatory response syndrome.
Across multi-cohort transcriptomic analyses, a 12-gene panel distinguished sepsis from SIRS with near-perfect discrimination (AUC 0.998; external AUCs >0.93). Mendelian randomization supported EIF4G3 as causally linked to sepsis risk, hub genes localized to myeloid cells by scRNA-seq, and EIF4G3/DNAJC5 upregulation was experimentally validated.
Impact: Delivers a diagnostically strong, externally validated gene signature and elevates biomarker discovery by integrating causal inference and single-cell mapping.
Clinical Implications: If prospectively validated, the 12-gene panel could enable rapid differentiation of sepsis from sterile SIRS to guide antimicrobials and resource allocation. EIF4G3 and DNAJC5 may serve as targeted diagnostic readouts.
Key Findings
- A 12-gene signature built with LASSO + Random Forest achieved AUC 0.998; external validations had AUCs >0.93.
- Two-sample Mendelian randomization supported a causal role of elevated EIF4G3 in sepsis risk.
- scRNA-seq localized hub gene expression (e.g., DNAJC5) to myeloid cells; EIF4G3 and DNAJC5 upregulation was confirmed in vitro and in vivo.
Methodological Strengths
- Evaluation of 113 ML models with robust external validation across datasets
- Integration of causal inference (two-sample MR) and single-cell localization with experimental validation
Limitations
- Retrospective secondary analyses; prospective, real-time clinical validation is lacking
- Implementation feasibility, turnaround time, and cost-effectiveness in acute care settings remain unassessed
Future Directions: Prospective multicenter validation with predefined thresholds, development of rapid assays (e.g., qPCR panels), and assessment of clinical impact on antibiotic stewardship and outcomes.
BACKGROUND: Sepsis, a life-threatening condition driven by a dysregulated host response, poses significant challenges for early diagnosis and early intervention. This study aimed to identify robust biomarkers capable of distinguishing sepsis from non-infectious systemic inflammation (SIRS). METHODS: We analyzed public Gene Expression Omnibus (GEO) data sets using a multi-modal workflow. This included differential expression analysis, weighted gene co-expression network analysis (WGCNA), and an evaluation of 113 machine learning (ML) models to build a predictive signature. We further investigated hub genes using immune infiltration, single-cell RNA sequencing (scRNA-seq), and two-sample Mendelian randomization (MR) to infer causality. Key findings were validated experimentally (in vitro and in vivo). RESULTS: The optimal LASSO + RF model identified a 12-gene signature strongly associated with the septic state, achieving a high area under the curve (AUC) of 0.998 and robust external validation (AUCs > 0.93). This high discriminatory power highlights its potential for stratifying patients. Notably, MR analysis provided causal evidence linking elevated EIF4G3 expression to increased sepsis risk. ScRNA-seq located the expression of hub genes, including DNAJC5, to myeloid cells. Experimental validation confirmed the upregulation of EIF4G3 and DNAJC5 in sepsis models. CONCLUSIONS: This study identifies and validates a highly accurate 12-gene signature for distinguishing sepsis from SIRS. The causal evidence for EIF4G3 and robust validation of DNAJC5 underscore their potential as biomarkers for early diagnosis and differentiation from SIRS. This signature holds significant promise for the early identification of high-risk patients, enabling timely intervention and improving outcomes.
3. Aging-caused the changes of the gut microbiota drive intestinal barrier dysfunction and increase sepsis susceptibility.
Through fecal microbiota transplantation from aged versus young septic donors into pseudo-germ-free mice, the study links aging-associated microbiota to intestinal barrier dysfunction and greater sepsis susceptibility. Multi-omics profiling and engineered bacterial strains support causal roles for specific taxa and metabolites.
Impact: Provides causal evidence connecting aging microbiota to gut barrier failure in sepsis, a key driver of systemic inflammation and outcomes in older adults.
Clinical Implications: Findings motivate microbiome-targeted strategies—donor selection for FMT, pre/probiotics, or metabolite modulation—to protect gut barrier integrity and reduce sepsis risk in the elderly.
Key Findings
- FMT from aged septic humans and mice into young pseudo-germ-free mice was used to probe causal effects on gut barrier function and sepsis susceptibility.
- 16S rDNA sequencing, histology, ELISA, and FITC-dextran assays characterized microbiota composition, inflammation, and intestinal permeability.
- Untargeted and targeted metabolomics identified differential metabolites; engineered bacteria validated roles of specific strains/metabolites in sepsis contexts.
Methodological Strengths
- Cross-species donor FMT into controlled pseudo-germ-free murine recipients to test causality
- Integrated multi-omics (16S sequencing and metabolomics) with engineered bacterial validation
Limitations
- Abstract does not report quantitative effect sizes or specific taxa/metabolites; full dataset details are needed
- Preclinical murine recipient model limits direct generalizability to human clinical outcomes
Future Directions: Define specific taxa and metabolites mediating barrier dysfunction, test targeted microbiome and metabolite interventions, and evaluate translational endpoints in aged human cohorts.
Physiological and pathological changes associated with aging contribute to deteriorating disease prognosis in sepsis. However, the mechanisms by which these disturbances exacerbate inflammation remain underexplored. In this study, fecal samples were collected from aged and young septic patients and mice and subsequently transplanted into young pseudo-germ-free mice via fecal microbiota transplantation. Fecal, colon tissue, and blood samples were collected to be used 16S rDNA sequencing to characterize the gut microbiota, histopathological examination, enzyme-linked immunosorbent assay and FITC-dextran intestinal permeability assay to assess gut injury and gut barrier function. Additionally, nontargeted and targeted metabolomics were used to identify differential metabolites in the feces of aged and young septic mice. To further validate the roles of specific bacterial strains and their metabolites in sepsis, genetically engineered bacteria were used in both